Catalyst
Slingshot members are tracking this event:
Phase 1/2 topline data of Necuparanib (MOM-M402-103) for advanced metastatic pancreatic cancer due 2H 2017 - Discontinued
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MNTA |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 04, 2016
Occurred Source:
http://adisinsight.springer.com/drugs/800022260
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Necuparanib, Mom-m402-103, Phase 2 Study
